HC Wainwright Brokers Reduce Earnings Estimates for RYTM

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Analysts at HC Wainwright lowered their Q1 2026 earnings estimates for Rhythm Pharmaceuticals in a note issued to investors on Monday, March 2nd. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.84) per share for the quarter, down from their prior forecast of ($0.69). HC Wainwright has a “Buy” rating and a $110.00 price target on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q2 2026 earnings at ($0.82) EPS, Q3 2026 earnings at ($0.65) EPS, Q4 2026 earnings at ($0.56) EPS, FY2026 earnings at ($2.88) EPS, Q1 2027 earnings at ($0.34) EPS, Q2 2027 earnings at $0.09 EPS, Q3 2027 earnings at $0.42 EPS and Q4 2027 earnings at $0.88 EPS.

Several other research analysts have also commented on the company. Stifel Nicolaus set a $131.00 price target on Rhythm Pharmaceuticals in a research report on Thursday, February 26th. Needham & Company LLC decreased their price target on shares of Rhythm Pharmaceuticals from $148.00 to $139.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. TD Cowen restated a “buy” rating on shares of Rhythm Pharmaceuticals in a report on Thursday, December 11th. Guggenheim boosted their price objective on shares of Rhythm Pharmaceuticals from $140.00 to $143.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Finally, UBS Group reissued a “buy” rating on shares of Rhythm Pharmaceuticals in a research report on Wednesday, December 17th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $132.07.

Rhythm Pharmaceuticals Stock Up 0.5%

Shares of NASDAQ:RYTM opened at $91.46 on Wednesday. The firm has a 50 day moving average of $102.24 and a 200 day moving average of $103.34. The company has a market capitalization of $6.25 billion, a price-to-earnings ratio of -29.41 and a beta of 2.06. Rhythm Pharmaceuticals has a 52 week low of $45.90 and a 52 week high of $122.20.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its earnings results on Thursday, February 26th. The company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.06. Rhythm Pharmaceuticals had a negative net margin of 103.57% and a negative return on equity of 266.56%. The business had revenue of $57.25 million for the quarter, compared to the consensus estimate of $56.16 million. During the same quarter last year, the firm posted ($0.72) EPS. The company’s revenue for the quarter was up 36.9% on a year-over-year basis.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Invesco Ltd. boosted its position in Rhythm Pharmaceuticals by 102.8% in the fourth quarter. Invesco Ltd. now owns 291,150 shares of the company’s stock valued at $31,165,000 after buying an additional 147,595 shares during the last quarter. Empowered Funds LLC raised its position in Rhythm Pharmaceuticals by 94.1% during the 4th quarter. Empowered Funds LLC now owns 4,164 shares of the company’s stock worth $446,000 after buying an additional 2,019 shares during the last quarter. XTX Topco Ltd acquired a new stake in Rhythm Pharmaceuticals during the 4th quarter valued at approximately $1,117,000. Wellington Management Group LLP boosted its holdings in shares of Rhythm Pharmaceuticals by 922.0% in the 4th quarter. Wellington Management Group LLP now owns 250,156 shares of the company’s stock valued at $26,777,000 after acquiring an additional 225,679 shares during the last quarter. Finally, SummitTX Capital L.P. boosted its holdings in shares of Rhythm Pharmaceuticals by 580.2% in the 4th quarter. SummitTX Capital L.P. now owns 80,729 shares of the company’s stock valued at $8,641,000 after acquiring an additional 68,860 shares during the last quarter.

Insiders Place Their Bets

In other Rhythm Pharmaceuticals news, insider Pamela J. Cramer sold 3,350 shares of Rhythm Pharmaceuticals stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $111.00, for a total transaction of $371,850.00. Following the completion of the sale, the insider owned 20,814 shares of the company’s stock, valued at approximately $2,310,354. The trade was a 13.86% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Hunter C. Smith sold 4,385 shares of the business’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $101.26, for a total value of $444,025.10. Following the sale, the chief financial officer owned 110,512 shares in the company, valued at approximately $11,190,445.12. The trade was a 3.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 25,003 shares of company stock valued at $2,589,015. Corporate insiders own 6.10% of the company’s stock.

Rhythm Pharmaceuticals News Roundup

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: H.C. Wainwright keeps a “Buy” rating and models a return to positive quarterly EPS in 2027 (e.g., Q2 2027 +$0.09, Q3 2027 +$0.42, Q4 2027 +$0.88), implying a path to profitability that supports longer‑term upside. What is HC Wainwright’s Forecast for RYTM FY2027 Earnings?
• Positive Sentiment: Recent company results showed revenue and EPS beats (Q4 revenue up ~36.9% YoY and EPS slightly better than estimates), supplying fundamental support for the stock’s near‑term strength. No link
• Neutral Sentiment: Trading interest is moderate: intraday volume (~662k) is below the stock’s average (~789k), and the shares remain below both the 50‑day ($102.24) and 200‑day ($103.34) moving averages — mixed technical signals for traders. No link
• Negative Sentiment: H.C. Wainwright trimmed near‑term estimates and lowered its price target to $110 from $125 while cutting FY2026 and several 2026 quarterly EPS forecasts (FY2026 to -$2.88 from -$1.98; multiple quarters revised deeper into loss), which reduces near‑term upside and could pressure the stock. Price target lowered to $110 from $125 at H.C. Wainwright

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.